Reclassifying cannabis to a Schedule III drug would put the U.S. in noncompliance with the international treaty Single Convention on Narcotic Drugs, 1961. Will this create a barrier for the U.S. in its scheduling review, and if so, to what extent? Historian James H. Mills weighs in.